167 related articles for article (PubMed ID: 16213195)
1. Development of specific Rho-kinase inhibitors and their clinical application.
Tamura M; Nakao H; Yoshizaki H; Shiratsuchi M; Shigyo H; Yamada H; Ozawa T; Totsuka J; Hidaka H
Biochim Biophys Acta; 2005 Dec; 1754(1-2):245-52. PubMed ID: 16213195
[TBL] [Abstract][Full Text] [Related]
2. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway.
Sasaki Y; Suzuki M; Hidaka H
Pharmacol Ther; 2002; 93(2-3):225-32. PubMed ID: 12191614
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacological analysis of Rho-kinase inhibitors and identification of molecular components of Ca2+ sensitization in the rat lower urinary tract.
Teixeira CE; Jin L; Priviero FB; Ying Z; Webb RC
Biochem Pharmacol; 2007 Aug; 74(4):647-58. PubMed ID: 17603024
[TBL] [Abstract][Full Text] [Related]
4. Functional roles of the rho/rho kinase pathway and protein kinase C in the regulation of cerebrovascular constriction mediated by hemoglobin: relevance to subarachnoid hemorrhage and vasospasm.
Wickman G; Lan C; Vollrath B
Circ Res; 2003 Apr; 92(7):809-16. PubMed ID: 12637369
[TBL] [Abstract][Full Text] [Related]
5. [Involvement of small GTPase Rho and Rho-kinase in the pathogenesis of hypertension and hypertensive target organ damage].
Nakayama M; Amano M; Kawabata S; Kaibuchi K; Takefuji M
Nihon Rinsho; 2004 Mar; 62 Suppl 3():202-6. PubMed ID: 15171369
[No Abstract] [Full Text] [Related]
6. Rho kinase inhibitors block activation of pancreatic stellate cells.
Masamune A; Kikuta K; Satoh M; Satoh K; Shimosegawa T
Br J Pharmacol; 2003 Dec; 140(7):1292-302. PubMed ID: 14581180
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.
Abe K; Shimokawa H; Morikawa K; Uwatoku T; Oi K; Matsumoto Y; Hattori T; Nakashima Y; Kaibuchi K; Sueishi K; Takeshit A
Circ Res; 2004 Feb; 94(3):385-93. PubMed ID: 14670839
[TBL] [Abstract][Full Text] [Related]
8. [Rho-kinase inhibitor].
Ohnaka K; Takayanagi R
Nihon Rinsho; 2004 Feb; 62 Suppl 2():571-4. PubMed ID: 15035192
[No Abstract] [Full Text] [Related]
9. Synthesis and pharmacological study of Rho-kinase inhibitors: pharmacomodulations on the lead compound Fasudil.
Logé C; Siomboing X; Wallez V; Scalbert E; Bennejean C; Cario-Tourmaniantz C; Loirand G; Gressier B; Pacaud P; Luyckx M
J Enzyme Inhib Med Chem; 2003 Apr; 18(2):127-38. PubMed ID: 12943196
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of contractility in rat epididymal vas deferens by Rho kinase inhibitors.
Amobi NI; Chung IP; Smith IC
Auton Autacoid Pharmacol; 2006 Apr; 26(2):169-81. PubMed ID: 16553645
[TBL] [Abstract][Full Text] [Related]
11. Rho/Rho kinase as a potential target for the treatment of renal disease.
Wakino S; Kanda T; Hayashi K
Drug News Perspect; 2005 Dec; 18(10):639-43. PubMed ID: 16491166
[TBL] [Abstract][Full Text] [Related]
12. Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm.
Kandabashi T; Shimokawa H; Miyata K; Kunihiro I; Eto Y; Morishige K; Matsumoto Y; Obara K; Nakayama K; Takahashi S; Takeshita A
Arterioscler Thromb Vasc Biol; 2003 Dec; 23(12):2209-14. PubMed ID: 14592852
[TBL] [Abstract][Full Text] [Related]
13. Y-27632, an inhibitor of Rho-associated kinases, prevents tyrosine phosphorylation of focal adhesion kinase and paxillin induced by bombesin: dissociation from tyrosine phosphorylation of p130(CAS).
Sinnett-Smith J; Lunn JA; Leopoldt D; Rozengurt E
Exp Cell Res; 2001 Jun; 266(2):292-302. PubMed ID: 11399057
[TBL] [Abstract][Full Text] [Related]
14. The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells.
Burthem J; Rees-Unwin K; Mottram R; Adams J; Lucas GS; Spooncer E; Whetton AD
Leukemia; 2007 Aug; 21(8):1708-14. PubMed ID: 17554385
[TBL] [Abstract][Full Text] [Related]
15. Expression of Rho-kinase (ROCK-1 and ROCK-2) and its substantial role in the contractile activity of the sheep ureter.
Levent A; Büyükafsar K
Br J Pharmacol; 2004 Oct; 143(3):431-7. PubMed ID: 15351780
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C is necessary for recovery from the thyrotropin-releasing hormone-induced r-ERG current reduction in GH3 rat anterior pituitary cells.
Gomez-Varela D; Giraldez T; de la Pena P; Dupuy SG; Garcia-Manso D; Barros F
J Physiol; 2003 Mar; 547(Pt 3):913-29. PubMed ID: 12562894
[TBL] [Abstract][Full Text] [Related]
17. Rho kinase inhibitor improves motor dysfunction and hypoalgesia in a rat model of lumbar spinal canal stenosis.
Ito T; Ohtori S; Hata K; Inoue G; Moriya H; Takahashi K; Yamashita T
Spine (Phila Pa 1976); 2007 Sep; 32(19):2070-5. PubMed ID: 17762807
[TBL] [Abstract][Full Text] [Related]
18. [Role of the Rho/Rho-kinase pathway in the development of hypertensive glomerulosclerosis: renoprotective effect of Rho-kinase inhibitor in hypertensive glomerulosclerosis and its molecular mechanism].
Nishikimi T
Nihon Yakurigaku Zasshi; 2006 Sep; 128(3):153-9, 152. PubMed ID: 16971778
[No Abstract] [Full Text] [Related]
19. Selectivity of ROCK inhibitors in the spontaneously tonic smooth muscle.
Rattan S; Patel CA
Am J Physiol Gastrointest Liver Physiol; 2008 Mar; 294(3):G687-93. PubMed ID: 18187514
[TBL] [Abstract][Full Text] [Related]
20. Proerectile effects of the Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine (H-1152) in the rat penis.
Teixeira CE; Ying Z; Webb RC
J Pharmacol Exp Ther; 2005 Oct; 315(1):155-62. PubMed ID: 15976017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
